ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Moves To Revoke Avastin’s Breast Cancer Accelerated Approval, Genentech Vows To Fight

December 17, 2010

In Brief: DCCR Advisory Committee Meeting Rescheduled; Durant To Head Cooperative Group Chairman

June 29, 1979

Vitamin D Not Associated With Risk For Less Common Cancers, Study Finds

July 30, 2010

Idaho Senator Pressure DeVita On Taking Neutron Facility

May 6, 1988

Two OAM Advisors Criticize Third over ACS Membership

July 23, 1993

HEW Says Patent Delays Temporary

August 25, 1978